Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
MARKET WRAP: NZ shares flat on mixed trading

2018-07-17 nbr.co.nz
Hamilton Hindin Greene investment adviser Grant Davies says Steel & Tube was “probably due” a good trading day.
FBU FBU FCREY NZR FRCEF PGWFF PGW PGWFY

0
NZ shares mixed, A2, Kathmandu weaken

2018-07-17 nzherald.co.nz
New Zealand shares were mixed, with Kathmandu Holdings and A2 Milk dragging the index lower while defensive stocks such as Investore made gains amidst global uncertainty.
KTHDY GNE FBU FBU FCREY GNE FRCEF KMD GEL SML KMD

0
Fletcher Building appoints new head to deal with construction

2018-07-15 radionz.co.nz
Fletcher Building is making further changes to its top management as it appoints a new construction business head.
FBU FBU FCREY FRCEF

0
Fletcher appoints Peter Reidy CEO of its construction problem child

2018-07-15 nbr.co.nz
Fletcher Building has appointed a new chief executive to its construction division, Peter Reidy, who is KiwiRail’s chief executive, and also moved current chief executive, Michelle Kernahan, to head the building products division.
FBU FBU FCREY FRCEF

0
Fletcher Building nabs Kiwirail CEO Peter Reidy to head construction arm

2018-07-15 nzherald.co.nz
Fletcher Building has picked up KiwiRail chief executive Peter Reidy to head the company's construction division, which oversees the problematic Buildings + Interiors unit.
FBU FBU FCREY FRCEF

0
Farmlands takes honours in survey of Kiwi brands

2018-07-12 nbr.co.nz
The Farmlands Co-operative Society has emerged as the top New Zealand brand in a KPMG survey that asked customers of different countries to rate brands on various criteria related to customer experience.
CEN FBU AIR FCREY FRCEF ANZFY COENY AIZ COENF FBU ANZLY CEN ANZFF

1
Steel & Tube says it struggled against bigger rivals in irrigation sector

2018-07-10 nzherald.co.nz
Steel & Tube Holdings' new chief executive Mark Malpass says the company paid too much to enter the irrigation sector, struggled to compete against bigger rivals and ended up writing off its investment to return focus to its core steel business.
FBU FBU FCREY FRCEF

0
NZ stock index rises to record

2018-07-06 nzherald.co.nz
New Zealand's benchmark stock index rose to a record, with Fletcher Building and Sky Network Television gaining while Scales and NZX dropped.
SKT FBU SYKWF RHCGF FBU FCREY RYHTY SKKTY RYM FRCEF

0
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

6
Foreign investors purchase $2.1 billion of NZ assets in first five months of the year

2018-07-02 nzherald.co.nz
Foreigners got consent to buy $2.1 billion of New Zealand assets classed as rural, sensitive or worth $100m-plus in the first five months of the year.
FBU FBU FCREY FRCEF

12
Brian Gaynor: Bring greater diversity to the boardroom

2018-06-29 nzherald.co.nz
The Blues' success in the State of Origin thriller and the referee's decisions that supposedly robbed the Wallabies against Ireland weren't the only topics of conversation in Sydney this week.
WYN FBU FBU ANZLY AIR MPP FCREY MTPGF ANZFF ANZFY FRCEF AIZ

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

6
Fletcher Building sells stake in Sims Pacific Metals

2018-06-28 nzherald.co.nz
Fletcher Building is selling its stake in metal recycling company Sims Pacific Metals for $42 million as part of its new strategy to refocus on core businesses.
FBU FBU FCREY FRCEF

14
MARKET WRAP: NZ shares rise as Air NZ lands in hot water

2018-06-27 nbr.co.nz
Fat Prophets head of research Greg Smith says Synlait Milk Investors are responding well to Leon Clement's appointment.
FBU FBU ANZLY AIR FCREY ANZFF NZR ANZFY FRCEF AIZ SML

14
MARKET WRAP: NZ shares flat after mixed trading

2018-06-25 nbr.co.nz
The New Zealand market was flat today, as the market digested a strong period of growth.
FBU FBU ANZLY AIR FCREY ANZFF ANZFY FRCEF AIZ SML

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

2h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...